Literature DB >> 16828940

Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only.

Sandra L Giannini1, Emmanuel Hanon, Philippe Moris, Marcelle Van Mechelen, Sandra Morel, Francis Dessy, Marc A Fourneau, Brigitte Colau, Joann Suzich, Genevieve Losonksy, Marie-Thérèse Martin, Gary Dubin, Martine A Wettendorff.   

Abstract

An effective virus-like particle (VLP) based prophylactic vaccine designed to protect against persistent infection with human papillomavirus (HPV) types 16 and 18 and subsequent lesion development will need to induce a strong humoral and cellular immune response capable of providing long-term protection. Our objective was to evaluate the ability of an HPV16/18 L1 VLP vaccine formulated with the AS04 adjuvant system (3-O-desacyl-4'-monophosphoryl lipid A (MPL) and aluminium salt) to induce an immune response of higher magnitude and persistence compared to a vaccine formulated with aluminium salt only. We demonstrated that MPL adsorbed onto aluminium salt retains its capacity to activate an innate immune response as assessed by the production of TNFalpha by human monocytes (U937). In addition, vaccination of mice, monkeys or human subjects with AS04 formulations induced higher total anti-L1 VLP16 and L1 VLP18 antibody responses (1.6-8.5-fold) than the aluminium salt only formulations. The enhanced antibody response induced by the AS04 vaccine formulation (1.6-4.1-fold) in monkeys and humans was shown to be targeted to functional neutralising L1 VLP16 and L1 VLP18 epitopes as assessed by V5/J4 specific ELISAs or HPV16 and HPV18 pseudo-neutralization assays. The enhanced immune profile observed with the AS04 formulation in terms of both total, V5/J4 specific and neutralizing antibodies was shown to persist for at least 3.5-year post-vaccination in human subjects. Finally, using the newly developed B cell ELISPOT assay we also demonstrated that the AS04 formulation elicited an increased frequency (2.2-5.2-fold) of HPV L1 VLP specific memory B cells when compared with the aluminium salt only formulations. These data strongly support the role of the AS04 adjuvant, which includes the immunostimulant MPL, in triggering a persistent vaccine-induced immune response of high quality.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16828940     DOI: 10.1016/j.vaccine.2006.06.005

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  143 in total

1.  Vaccine adjuvants aluminum and monophosphoryl lipid A provide distinct signals to generate protective cytotoxic memory CD8 T cells.

Authors:  Megan K L MacLeod; Amy S McKee; Alexandria David; Jieru Wang; Robert Mason; John W Kappler; Philippa Marrack
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-25       Impact factor: 11.205

Review 2.  Squamous cell carcinomas of the head and neck in Fanconi anemia: risk, prevention, therapy, and the need for guidelines.

Authors:  K Scheckenbach; M Wagenmann; M Freund; J Schipper; H Hanenberg
Journal:  Klin Padiatr       Date:  2012-04-13       Impact factor: 1.349

3.  Transcriptional profiling of TLR-4/7/8-stimulated guinea pig splenocytes and whole blood by bDNA assay.

Authors:  Lance K Ching; Farah Mompoint; Jeffrey A Guderian; Alex Picone; Ian M Orme; Rhea N Coler; Steven G Reed; Susan L Baldwin
Journal:  J Immunol Methods       Date:  2011-08-03       Impact factor: 2.303

4.  Proteasome-independent major histocompatibility complex class I cross-presentation mediated by papaya mosaic virus-like particles leads to expansion of specific human T cells.

Authors:  Denis Leclerc; Diane Beauseigle; Jérome Denis; Hélène Morin; Christine Paré; Alain Lamarre; Réjean Lapointe
Journal:  J Virol       Date:  2006-11-22       Impact factor: 5.103

Review 5.  Prophylactic HPV vaccines.

Authors:  Margaret Stanley
Journal:  J Clin Pathol       Date:  2007-01-26       Impact factor: 3.411

Review 6.  Role of adjuvants in modeling the immune response.

Authors:  Darrick Carter; Steven G Reed
Journal:  Curr Opin HIV AIDS       Date:  2010-09       Impact factor: 4.283

7.  MF59 emulsion is an effective delivery system for a synthetic TLR4 agonist (E6020).

Authors:  Barbara C Baudner; Vanessa Ronconi; Daniele Casini; Marco Tortoli; Jina Kazzaz; Manmohan Singh; Lynn D Hawkins; Andreas Wack; Derek T O'Hagan
Journal:  Pharm Res       Date:  2009-03-03       Impact factor: 4.200

8.  Virus-like particles and capsomeres are potent vaccines against cutaneous alpha HPVs.

Authors:  Tilo Senger; Lysann Schädlich; Sonja Textor; Corinna Klein; Kristina M Michael; Christopher B Buck; Lutz Gissmann
Journal:  Vaccine       Date:  2009-12-08       Impact factor: 3.641

9.  Durability of Cross-Protection by Different Schedules of the Bivalent HPV Vaccine: The CVT Trial.

Authors:  Sabrina H Tsang; Joshua N Sampson; John Schussler; Carolina Porras; Sarah Wagner; Joseph Boland; Bernal Cortes; Douglas R Lowy; John T Schiller; Mark Schiffman; Troy J Kemp; Ana Cecilia Rodriguez; Wim Quint; Mitchell H Gail; Ligia A Pinto; Paula Gonzalez; Allan Hildesheim; Aimée R Kreimer; Rolando Herrero
Journal:  J Natl Cancer Inst       Date:  2020-10-01       Impact factor: 13.506

10.  Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials.

Authors:  John T Schiller; Douglas R Lowy
Journal:  J Infect Dis       Date:  2009-07-15       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.